#anti semma

[nikkiruncks]

Not EXACTLY Anti-S*mma, but I personally don’t recommend this for S*mma shippers to read.

I’m personally not into the idea that because Sean stood in front in of gun for Emma that “he’s still in love with her”.

Like first of all, Emma was about to DIE and Sean saved her life. Because he didn’t want her dead and he cared about her. If it was Jay or Toby, I still believe that Sean would’ve done the same thing. Because that’s the kind of guy Sean is.

Don’t me wrong, I do think Sean has love for Emma and does CARE about her. She was his first love, but I don’t think that translates into being in love with her.

[userlaylivia]

I'm rewatching degrassi and I'm not on the sellie seasons yet but I watched some videos and etc with them and I think I'll start liking them this time because they are cute and I never hated them but no matter if I start liking them together or not I'll always ship semma they are my bbs and one of my top otps on degrassi but I'm at the age now where I think I'll like sellie a lot more than before because I'm more open to it and lbr anything is better than spemma, I'll never ship that or understand it period lol

[leikeliscomet]

Saw a comparison between Zig x Maya to Emma x Sean and no. Just no. Sean messed up, but he always tried to make things better and grow from his mistakes. He always put Emma first even when they broke up. Zig on the other hand was hovering over every one of Maya relationships and couldn't accept her being happy with anyone but him. Sean warned Emma about Peter's manipulative antics because he had a track record of hurting people including her best friend. Zig called Maya sloppy seconds. Lets notttt

[fuzzychildchopshop]

Semma > Zaya

sorry not sorry

[cavixorg]

A biopharmaceutical firm in the clinical stages called Kintara Therapeutics, Inc. is dedicated to the creation and marketing of innovative cancer treatments. With a focused on orphan cancer indications, the company is creating and marketing anti-cancer treatments for people whose solid tumors display characteristics that make patients resistant to or unlikely to react to existing therapies. The two leading possibilities for the company are VAL-083 and REM-001. Its VAL-083 is a brand-new, approved deoxyribonucleic acid (DNA) targeted agent for the treatment of narcotic solid malignancies such diffuse intrinsic pontine glioma, glioblastoma multiforme. And maybe other solid tumors like ovarian cancer and non-small cell lung cancer (DIPG) REM-001, a delayed photodynamic therapy (PDT) product from the company, is used to treat cutaneous metastatic breast cancer (CMBC). About Kintara Additionally, Kintara offers a unique, late-stage PDT technology that shows promise for treating localized visceral or cutaneous tumors as well as for other possible purposes. People with CMBC who had previously had chemotherapy and/or unsuccessful radiation therapy were enrolled in four Phase 2/3 drug testing to examine the effects of REM-001 therapy. The clinical efficacy of REM-001 in CMBC is currently 80% full remission of CMBC evaluable lesions, and there is a strong safety database of almost 1,100 patients across several indications. To save money, Kintara has suspended the REM-001 CMBC initiative. Who Founded Kintara? The company was established in 2010 and has its headquarters in Canada's Vancouver. We can list its founders as Dennis M. Brown, Jeffrey A. Bacha, Jeffrey Bacha. Since November 8, 2021, Robert E. Hoffman has served as president and chief executive officer, board chairman since June 2018, and director since April 2018. Inc. Aslan Pharmaceuticals He participates inside the Board of Directors as a member. Since October 2018, he has been on the board of directors. Since November 2020, he has also sat on the board of Antibe Therapeutics Inc., where he has served as chairman since May 2022. Editas Medicine, Fulcrum Therapeutics, or Semma Therapeutics are probable rivals and alternatives to Kintara Therapeutics. There are three investors in Kintara Therapeutics, including the Luxembourg National Research Fund and Lincoln Park Capital Fund. What Are Kintara's Academic Collaborations? University of Texas MD Anderson Cancer Center: The goal of Kintara Therapeutics' partnership with MDACC is to investigate how DNA damage response (DDR) pathways affect VAL-083's ability to kill ovarian cancer cells and the potential for combining it with other therapies like PARP inhibitors. University of California San Francisco: By speeding the development of this much needed new medication for GBM, UCSF played a crucial role in expanding patient access and serving as the primary clinical location for our initial clinical trial. UCSF is also testing VAL-083's efficacy versus pediatric elevated glioma and medulloblastoma subtypes, both as a single drug and in combination with other therapies. British Columbia University: The collaboration between Kintara Therapeutics and the University of British Columbia is focused on investigating the DNA repair response (DDR) to VAL-083 therapies in a variety of pediatric brain cancer subgroups (personalized drug treatment) and assessing the potential for topoisomerase inhibitor-combined therapies. Highlights Of The Company And Recent Developments a statement stating that three posters had been approved for presentation of data at the Society for Neuro-Oncology (SNO) Annual Conference in 2022. The 2022 SNO Annual Session will be held in Tampa, Florida, from November 16 to November 20, 2022. (September). Robert E. Hoffman, president and chief executive officer of Kintara, said, "We have focused our VAL-083 program in glioblastoma sufferers and are looking forward to reporting top-line findings in the worldwide registrational GBM AGILE Study before the end of 2023."

"We believe VAL-083 may be an extra tool to help this neglected condition," the statement reads. "GBM patients and clinicians are in need of more medicines to tackle this fatal disease." A Report On The Financial Results For The 2023 Fiscal Year Kintara had about $7.1 million in cash and equivalents as of September 30, 2022. For a net profit to the company of almost $1.9 million during the three months ending September 30, 2022, Kintara concluded the sale of ordinary KTRA stock under a sales contract with Lincoln Park. Kintara reported a net loss of about $4.6 million, or $0.07 per share, for the three months that ended on September 30, 2022, compared to a net loss of about $6.0 million. Or $0.25 per share, for the three months that ended on September 30, 2021. Reduced research and development costs as well as lower expenses for general and administrative were the main causes of the lower net loss for the three months that ended September 30, 2022 as compared to the three months ending September 30, 2021. Kintara Therapeutics Stock Purchase Procedure Pick a location to purchase Kintara Therapeutics shares. Selecting a stock brokerage is necessary. Open a trading account. Enroll in 0% commission betting with the top brokerage we could find. The greatest location to get KTRA stock is there. Your brokerage account with the money. Add your details and choose your payment method. Analyze the stock of Kintara Therapeutics. The ticker symbol for Kintara Therapeutics is KTRA. Complete the KTRA transaction. Choose whether to buy KTRA stock using a limit order to acquire it at a specific price or at the current market rate. Get up-to-date information on your KTRA investment. Make a watchlist of important updates about your Kintara Therapeutics stock investment. Is This A Good Time To Purchase Shares Of Kintara Therapeutics? The average analyst rating for Kintara Therapeutics among the three Wall Street analysts who follow KTRA is "Hold." On September 29, 2022, Jason McCarthy, a Maxim Group bottom 2% analyst, downgrades KTRA to a hold rating. On May 16, 2022, Jason Kolbert, a Dawson James bottom 7% analyst, downgrades KTRA to a hold rating. On January 20, 2022, Michael King, a bottom 7% analyst at HC Wainwright & Co., keeps KTRA with a buy recommendation but decreases their price objective from $6.00 to $3.00.   Kintara Declares A Reverse One-For-Fifty Stock Split The 1-for-50 reverse KTRA stock split of Kintara's authorized and outstanding common stock will take effect at 5:00 p.m. (EST) on November 11, 2022. Kintara is a biopharmaceutical firm that focuses on the development of innovative solid tumor cancer medicines. The Nasdaq Capital Market will continue to list Kintara's common shares under the ticker "KTRA" and a new CUSIP code, 49720K200. On November 14, 2022, when the market opens, Kintara's common stock will start trading on The Nasdaq Capital Market on a reverse stock divide basis. In order to continue being listed on The Nasdaq Capital Market, Kintara's common stock must trade at a minimum bid price of $1.00 per share, which will be met by the reverse stock split (Nasdaq Listing Rule 5550(a)(2)). Every fifty pre-split shares of ordinary shares that are now outstanding and authorized will be automatically combined into one new share of common stock as a result of the reverse stock split without even any action on the part of the stockholders. Number Of Authorized Shares Of Stocks There will be around 1,616,146 outstanding and issued shares of stockholders as opposed to the 80,807,316 that were granted and current as of November 8, 2022. There will be a drop in the authorized common stock shares from 275,000,000 to 5,500,000. In accordance with the reversal stock split, no mutual funds will be distributed. No stockholders will receive money in lieu of fractional shares as a result of the reverse stock split; rather, any preferred stock of common stock will be rounded up to the closest whole post-split sh

are. The criminal records, vesting units, and stock options of Kintara will also be subject to the reverse stock split, with the conversion and exercise prices thereof being adjusted in accordance with the terms of those securities. The backward stock split will also apply to common shares issuable upon the converting of Kintara's outstanding company stock. What Is The Current Value Of Kintara Stock? KTRA (NASDAQ: ) There are 1,616,146 shares of Kintara Therapeutics outstanding at the moment. The market capitalization of Kintara Therapeutics stock, which is currently trading at $4.43 per share, is $7.05M. On February 22, 2013, Kintara Therapeutics stock went public at a price of $3,400.00. Your return over the past nine years if you had purchased Kintara Therapeutics stock at $3,400.00 would also be -99.87%, for an annualized return of -52.28%. Due Diligence Examines According to our assessment of its fair market value cost of $16.45 depending on discounted cash (DCF) modeling, KTRA ($4.43) is overvalued by 73.5%, but it does not have a substantial margin of safety.  According to our assessment of KTRA's fair value cost of $16.45 based on discounted cash (DCF) modeling, which includes a strong margin of safety, the KTRA stock is currently markedly undervalued at $4.43, a difference of 73.5%. We cannot determine KTRA's intrinsic value using a revised list of Benjamin Graham's method from "The Intelligent Investor" since KTRA is not profitable. In three years, KTRA's Return on Equity is expected to be strong (24.87%); analysts are optimistic about the company's capacity to effectively create return on equity. In comparison to the US Biotechnology sector average (12.5%), KTRA stock forecast is predicted to produce a better Return on Assets (18.11%). The Return on Equity (-193%) of KTRA demonstrates a business that is ineffective at converting shareholders ’ equity into returns. The US Biotechnology sector average (2.32%) is higher than KTRA's Return on Assets (-145.2%). When compared to three years ago (-109.07%), KTRA's capacity to produce Return on Capital has reduced (-220.17%). What Is The Target Price For Kintara? The average KTRA price goal is $3.00, with the top and cheapest KTRA stock forecast both coming in at $3.00, according to one Wall Street analyst who has published a KTRA price target for the next year. By September 29, 2023, the Wall Street analyst projected that Kintara Therapeutics' share price may reach $3.00. From the present KTRA share price of $4.36, the consensus Kintara Therapeutics stock price projection predicts a potential decline of 31.19%. Kintara Therapeutics Stock Price Forecast For 2023 At the time of writing, one share of KTRA stock costs roughly $4.43. Kintara Therapeutics' stock has 3 1 year target prices from Wall Street analysts. Their predictions for the price of KTRA stock forecast range from $150 to $150. They anticipate that within a year, the actual share price will rise to $150. This represents a potential increase from of the stock's market valuation of 3,380.3%. From the most recent price of 4.50, the consensus KTRA stock forecast reflects a +3,182.28% rise. Currently, there is agreement among the two investment analysts that were surveyed to hold Kintara Therapeutics Inc. shares. Until September, when it stayed constant from a hold rating, this rating has remained stable. KTRA Stock Forecast 2024 The revenue for Kintara Therapeutics in 2022 is zero. With the lowest KTRA stock forecast at $31,741,107 and the highest KTRA stock forecast at $31,741,107, 1 Wall Street analysts expect KTRA's revenue will be $31,741,107 on average in 2023. With the lowest KTRA stock forecast coming in at $146,956,156 and the highest KTRA stock forecast coming in at $146,956,156, 1 Wall Street analysts expect KTRA to generate $146,956,156 in revenue in 2024 on average. KTRA Stock Forecast 2025 The revenue for Kintara Therapeutics in 2022 is -$21,661,000. With the cheapest

KTRA stock forecast prognosis being $48,484 and the greatest KTRA earnings projection being $48,484, 1 Wall Street analyst estimated KTRA's earnings to be $48,484 on average for 2023. KTRA stock forecast are expected to be $905,042 on average in 2024, according to one Wall Street analyst, with the lowest and highest estimates both being $905,042. KTRA stock forecast to earn $2,391,896 in 2025, with the lowest and greatest estimates of earnings both coming in at $2,391,896. KTRA is anticipated to create $362,016,704 in revenue in 2025, with $362,016,704 as the lowest and $362,016,704 as the highest revenue projections. Paying dividends is not a source of income for Kintara Therapeutics.  

[stocklivemarket]

A biopharmaceutical firm in the clinical stages called Kintara Therapeutics, Inc. is dedicated to the creation and marketing of innovative cancer treatments. With a focused on orphan cancer indications, the company is creating and marketing anti-cancer treatments for people whose solid tumors display characteristics that make patients resistant to or unlikely to react to existing therapies. The two leading possibilities for the company are VAL-083 and REM-001. Its VAL-083 is a brand-new, approved deoxyribonucleic acid (DNA) targeted agent for the treatment of narcotic solid malignancies such diffuse intrinsic pontine glioma, glioblastoma multiforme. And maybe other solid tumors like ovarian cancer and non-small cell lung cancer (DIPG) REM-001, a delayed photodynamic therapy (PDT) product from the company, is used to treat cutaneous metastatic breast cancer (CMBC). About Kintara Additionally, Kintara offers a unique, late-stage PDT technology that shows promise for treating localized visceral or cutaneous tumors as well as for other possible purposes. People with CMBC who had previously had chemotherapy and/or unsuccessful radiation therapy were enrolled in four Phase 2/3 drug testing to examine the effects of REM-001 therapy. The clinical efficacy of REM-001 in CMBC is currently 80% full remission of CMBC evaluable lesions, and there is a strong safety database of almost 1,100 patients across several indications. To save money, Kintara has suspended the REM-001 CMBC initiative. Who Founded Kintara? The company was established in 2010 and has its headquarters in Canada's Vancouver. We can list its founders as Dennis M. Brown, Jeffrey A. Bacha, Jeffrey Bacha. Since November 8, 2021, Robert E. Hoffman has served as president and chief executive officer, board chairman since June 2018, and director since April 2018. Inc. Aslan Pharmaceuticals He participates inside the Board of Directors as a member. Since October 2018, he has been on the board of directors. Since November 2020, he has also sat on the board of Antibe Therapeutics Inc., where he has served as chairman since May 2022. Editas Medicine, Fulcrum Therapeutics, or Semma Therapeutics are probable rivals and alternatives to Kintara Therapeutics. There are three investors in Kintara Therapeutics, including the Luxembourg National Research Fund and Lincoln Park Capital Fund. What Are Kintara's Academic Collaborations? University of Texas MD Anderson Cancer Center: The goal of Kintara Therapeutics' partnership with MDACC is to investigate how DNA damage response (DDR) pathways affect VAL-083's ability to kill ovarian cancer cells and the potential for combining it with other therapies like PARP inhibitors. University of California San Francisco: By speeding the development of this much needed new medication for GBM, UCSF played a crucial role in expanding patient access and serving as the primary clinical location for our initial clinical trial. UCSF is also testing VAL-083's efficacy versus pediatric elevated glioma and medulloblastoma subtypes, both as a single drug and in combination with other therapies. British Columbia University: The collaboration between Kintara Therapeutics and the University of British Columbia is focused on investigating the DNA repair response (DDR) to VAL-083 therapies in a variety of pediatric brain cancer subgroups (personalized drug treatment) and assessing the potential for topoisomerase inhibitor-combined therapies. Highlights Of The Company And Recent Developments a statement stating that three posters had been approved for presentation of data at the Society for Neuro-Oncology (SNO) Annual Conference in 2022. The 2022 SNO Annual Session will be held in Tampa, Florida, from November 16 to November 20, 2022. (September). Robert E. Hoffman, president and chief executive officer of Kintara, said, "We have focused our VAL-083 program in glioblastoma sufferers and are looking forward to reporting top-line findings in the worldwide registrational GBM AGILE Study before the end of 2023."

"We believe VAL-083 may be an extra tool to help this neglected condition," the statement reads. "GBM patients and clinicians are in need of more medicines to tackle this fatal disease." A Report On The Financial Results For The 2023 Fiscal Year Kintara had about $7.1 million in cash and equivalents as of September 30, 2022. For a net profit to the company of almost $1.9 million during the three months ending September 30, 2022, Kintara concluded the sale of ordinary KTRA stock under a sales contract with Lincoln Park. Kintara reported a net loss of about $4.6 million, or $0.07 per share, for the three months that ended on September 30, 2022, compared to a net loss of about $6.0 million. Or $0.25 per share, for the three months that ended on September 30, 2021. Reduced research and development costs as well as lower expenses for general and administrative were the main causes of the lower net loss for the three months that ended September 30, 2022 as compared to the three months ending September 30, 2021. Kintara Therapeutics Stock Purchase Procedure Pick a location to purchase Kintara Therapeutics shares. Selecting a stock brokerage is necessary. Open a trading account. Enroll in 0% commission betting with the top brokerage we could find. The greatest location to get KTRA stock is there. Your brokerage account with the money. Add your details and choose your payment method. Analyze the stock of Kintara Therapeutics. The ticker symbol for Kintara Therapeutics is KTRA. Complete the KTRA transaction. Choose whether to buy KTRA stock using a limit order to acquire it at a specific price or at the current market rate. Get up-to-date information on your KTRA investment. Make a watchlist of important updates about your Kintara Therapeutics stock investment. Is This A Good Time To Purchase Shares Of Kintara Therapeutics? The average analyst rating for Kintara Therapeutics among the three Wall Street analysts who follow KTRA is "Hold." On September 29, 2022, Jason McCarthy, a Maxim Group bottom 2% analyst, downgrades KTRA to a hold rating. On May 16, 2022, Jason Kolbert, a Dawson James bottom 7% analyst, downgrades KTRA to a hold rating. On January 20, 2022, Michael King, a bottom 7% analyst at HC Wainwright & Co., keeps KTRA with a buy recommendation but decreases their price objective from $6.00 to $3.00.   Kintara Declares A Reverse One-For-Fifty Stock Split The 1-for-50 reverse KTRA stock split of Kintara's authorized and outstanding common stock will take effect at 5:00 p.m. (EST) on November 11, 2022. Kintara is a biopharmaceutical firm that focuses on the development of innovative solid tumor cancer medicines. The Nasdaq Capital Market will continue to list Kintara's common shares under the ticker "KTRA" and a new CUSIP code, 49720K200. On November 14, 2022, when the market opens, Kintara's common stock will start trading on The Nasdaq Capital Market on a reverse stock divide basis. In order to continue being listed on The Nasdaq Capital Market, Kintara's common stock must trade at a minimum bid price of $1.00 per share, which will be met by the reverse stock split (Nasdaq Listing Rule 5550(a)(2)). Every fifty pre-split shares of ordinary shares that are now outstanding and authorized will be automatically combined into one new share of common stock as a result of the reverse stock split without even any action on the part of the stockholders. Number Of Authorized Shares Of Stocks There will be around 1,616,146 outstanding and issued shares of stockholders as opposed to the 80,807,316 that were granted and current as of November 8, 2022. There will be a drop in the authorized common stock shares from 275,000,000 to 5,500,000. In accordance with the reversal stock split, no mutual funds will be distributed. No stockholders will receive money in lieu of fractional shares as a result of the reverse stock split; rather, any preferred stock of common stock will be rounded up to the closest whole post-split sh

are. The criminal records, vesting units, and stock options of Kintara will also be subject to the reverse stock split, with the conversion and exercise prices thereof being adjusted in accordance with the terms of those securities. The backward stock split will also apply to common shares issuable upon the converting of Kintara's outstanding company stock. What Is The Current Value Of Kintara Stock? KTRA (NASDAQ: ) There are 1,616,146 shares of Kintara Therapeutics outstanding at the moment. The market capitalization of Kintara Therapeutics stock, which is currently trading at $4.43 per share, is $7.05M. On February 22, 2013, Kintara Therapeutics stock went public at a price of $3,400.00. Your return over the past nine years if you had purchased Kintara Therapeutics stock at $3,400.00 would also be -99.87%, for an annualized return of -52.28%. Due Diligence Examines According to our assessment of its fair market value cost of $16.45 depending on discounted cash (DCF) modeling, KTRA ($4.43) is overvalued by 73.5%, but it does not have a substantial margin of safety.  According to our assessment of KTRA's fair value cost of $16.45 based on discounted cash (DCF) modeling, which includes a strong margin of safety, the KTRA stock is currently markedly undervalued at $4.43, a difference of 73.5%. We cannot determine KTRA's intrinsic value using a revised list of Benjamin Graham's method from "The Intelligent Investor" since KTRA is not profitable. In three years, KTRA's Return on Equity is expected to be strong (24.87%); analysts are optimistic about the company's capacity to effectively create return on equity. In comparison to the US Biotechnology sector average (12.5%), KTRA stock forecast is predicted to produce a better Return on Assets (18.11%). The Return on Equity (-193%) of KTRA demonstrates a business that is ineffective at converting shareholders ’ equity into returns. The US Biotechnology sector average (2.32%) is higher than KTRA's Return on Assets (-145.2%). When compared to three years ago (-109.07%), KTRA's capacity to produce Return on Capital has reduced (-220.17%). What Is The Target Price For Kintara? The average KTRA price goal is $3.00, with the top and cheapest KTRA stock forecast both coming in at $3.00, according to one Wall Street analyst who has published a KTRA price target for the next year. By September 29, 2023, the Wall Street analyst projected that Kintara Therapeutics' share price may reach $3.00. From the present KTRA share price of $4.36, the consensus Kintara Therapeutics stock price projection predicts a potential decline of 31.19%. Kintara Therapeutics Stock Price Forecast For 2023 At the time of writing, one share of KTRA stock costs roughly $4.43. Kintara Therapeutics' stock has 3 1 year target prices from Wall Street analysts. Their predictions for the price of KTRA stock forecast range from $150 to $150. They anticipate that within a year, the actual share price will rise to $150. This represents a potential increase from of the stock's market valuation of 3,380.3%. From the most recent price of 4.50, the consensus KTRA stock forecast reflects a +3,182.28% rise. Currently, there is agreement among the two investment analysts that were surveyed to hold Kintara Therapeutics Inc. shares. Until September, when it stayed constant from a hold rating, this rating has remained stable. KTRA Stock Forecast 2024 The revenue for Kintara Therapeutics in 2022 is zero. With the lowest KTRA stock forecast at $31,741,107 and the highest KTRA stock forecast at $31,741,107, 1 Wall Street analysts expect KTRA's revenue will be $31,741,107 on average in 2023. With the lowest KTRA stock forecast coming in at $146,956,156 and the highest KTRA stock forecast coming in at $146,956,156, 1 Wall Street analysts expect KTRA to generate $146,956,156 in revenue in 2024 on average. KTRA Stock Forecast 2025 The revenue for Kintara Therapeutics in 2022 is -$21,661,000. With the cheapest

KTRA stock forecast prognosis being $48,484 and the greatest KTRA earnings projection being $48,484, 1 Wall Street analyst estimated KTRA's earnings to be $48,484 on average for 2023. KTRA stock forecast are expected to be $905,042 on average in 2024, according to one Wall Street analyst, with the lowest and highest estimates both being $905,042. KTRA stock forecast to earn $2,391,896 in 2025, with the lowest and greatest estimates of earnings both coming in at $2,391,896. KTRA is anticipated to create $362,016,704 in revenue in 2025, with $362,016,704 as the lowest and $362,016,704 as the highest revenue projections. Paying dividends is not a source of income for Kintara Therapeutics.  

[von-frappe]

if i had a nickel for every time a beloved character of mine returns for the sixth season of their respective shows, which also happens to be their final appearance, but it’s a big fat let down because they’re treated as nothing more than another characters love interest for the whole season… i’d have two nickels

[minamotoz]

semma in season 6 was written like it was meant to make shippers happy more than it was written to Be Good

[therezastarman]

i went to search for your blog and typed in “nico” 😳😐

anywayssss what little mix album would you like to see a glee tribute episode for?

jbasjd i do that all the time, especially with you and becky, not sure why i do that specifically with you two lmao

get weird-prom/sadie hawkins dance episode (s4 or 5)

black magic-girls trying to find dates.

love me like you-tina lamenting not having a date, she ends up dancing with a bunch of guys (and girls) while she's singing it.

weird people-blaine sings this at the dance as artie successfully spikes the punch bowl (because sue is busy in her office contemplating her blossoming feelings for emma) and there is a montage of the students getting progressively drunker and drunker.

secret love song- sue dreamily sings this song in her office while thinking about how she's falling for emma.

grown- will comes into sue's office right as she's singing the last notes of secret love song and starts very clearly, very badly flirting with sue. sue is fed up of this constantly happening and after kicking will out of her office, she calls up cooper and they sings grown together.

i love you- marley sings the ballad that is always in the prom episodes, she is making eye contact with unique the whole time.

i won't- (this is my story-line and therefore there are two prom queens). marley and unique win prom queens. they dance together (shut up, i know that it's a fast song) and kiss for the first time.

clued up- there is one last song in which sue and cooper realize that sue has forgotten about the dance and burst into the gym to find absolute chaos; all of the kids run.

[fandomlife-confessions]

[mayamatiln]

no matter how bad this fandom gets sometimes, I will always love the Degrassi fandom for collectively agreeing that Spemma being endgame was total bullshit and that she should have married Sean instead

[nikkiruncks]

Sean seeing Ellie’s cuts and knowing her demons yet not running vs Sean throwing a temper tantrum because Emma hooked up with Jay TWO YEARS ago.

[userlaylivia]

it's been years and spemma getting married will never make sense to me lol no ship on the show will ever make me scratch my head like spemma hooking up and getting married just ugh we all know semma was supposed to be endgame and the only reason they weren't is because sean went into the military like it was always supposed to be semma!! and daniel/miriam still being semma shippers and saying their back together now makes my heart happy because yessss!! she and spinner are divorced and she's back with sean, married now that's my story and I'm sticking to it!! like in what world do spemma make any sense lmao there's no way their not divorced now lol

[fuzzychildchopshop]

Semma > Zaya

Sorry, not sorry and no offense to Zaya shippers

[cavixorg]

A biopharmaceutical firm in the clinical stages called Kintara Therapeutics, Inc. is dedicated to the creation and marketing of innovative cancer treatments. With a focused on orphan cancer indications, the company is creating and marketing anti-cancer treatments for people whose solid tumors display characteristics that make patients resistant to or unlikely to react to existing therapies. The two leading possibilities for the company are VAL-083 and REM-001. Its VAL-083 is a brand-new, approved deoxyribonucleic acid (DNA) targeted agent for the treatment of narcotic solid malignancies such diffuse intrinsic pontine glioma, glioblastoma multiforme. And maybe other solid tumors like ovarian cancer and non-small cell lung cancer (DIPG) REM-001, a delayed photodynamic therapy (PDT) product from the company, is used to treat cutaneous metastatic breast cancer (CMBC). About Kintara Additionally, Kintara offers a unique, late-stage PDT technology that shows promise for treating localized visceral or cutaneous tumors as well as for other possible purposes. People with CMBC who had previously had chemotherapy and/or unsuccessful radiation therapy were enrolled in four Phase 2/3 drug testing to examine the effects of REM-001 therapy. The clinical efficacy of REM-001 in CMBC is currently 80% full remission of CMBC evaluable lesions, and there is a strong safety database of almost 1,100 patients across several indications. To save money, Kintara has suspended the REM-001 CMBC initiative. Who Founded Kintara? The company was established in 2010 and has its headquarters in Canada's Vancouver. We can list its founders as Dennis M. Brown, Jeffrey A. Bacha, Jeffrey Bacha. Since November 8, 2021, Robert E. Hoffman has served as president and chief executive officer, board chairman since June 2018, and director since April 2018. Inc. Aslan Pharmaceuticals He participates inside the Board of Directors as a member. Since October 2018, he has been on the board of directors. Since November 2020, he has also sat on the board of Antibe Therapeutics Inc., where he has served as chairman since May 2022. Editas Medicine, Fulcrum Therapeutics, or Semma Therapeutics are probable rivals and alternatives to Kintara Therapeutics. There are three investors in Kintara Therapeutics, including the Luxembourg National Research Fund and Lincoln Park Capital Fund. What Are Kintara's Academic Collaborations? University of Texas MD Anderson Cancer Center: The goal of Kintara Therapeutics' partnership with MDACC is to investigate how DNA damage response (DDR) pathways affect VAL-083's ability to kill ovarian cancer cells and the potential for combining it with other therapies like PARP inhibitors. University of California San Francisco: By speeding the development of this much needed new medication for GBM, UCSF played a crucial role in expanding patient access and serving as the primary clinical location for our initial clinical trial. UCSF is also testing VAL-083's efficacy versus pediatric elevated glioma and medulloblastoma subtypes, both as a single drug and in combination with other therapies. British Columbia University: The collaboration between Kintara Therapeutics and the University of British Columbia is focused on investigating the DNA repair response (DDR) to VAL-083 therapies in a variety of pediatric brain cancer subgroups (personalized drug treatment) and assessing the potential for topoisomerase inhibitor-combined therapies. Highlights Of The Company And Recent Developments a statement stating that three posters had been approved for presentation of data at the Society for Neuro-Oncology (SNO) Annual Conference in 2022. The 2022 SNO Annual Session will be held in Tampa, Florida, from November 16 to November 20, 2022. (September). Robert E. Hoffman, president and chief executive officer of Kintara, said, "We have focused our VAL-083 program in glioblastoma sufferers and are looking forward to reporting top-line findings in the worldwide registrational GBM AGILE Study before the end of 2023."

"We believe VAL-083 may be an extra tool to help this neglected condition," the statement reads. "GBM patients and clinicians are in need of more medicines to tackle this fatal disease." A Report On The Financial Results For The 2023 Fiscal Year Kintara had about $7.1 million in cash and equivalents as of September 30, 2022. For a net profit to the company of almost $1.9 million during the three months ending September 30, 2022, Kintara concluded the sale of ordinary KTRA stock under a sales contract with Lincoln Park. Kintara reported a net loss of about $4.6 million, or $0.07 per share, for the three months that ended on September 30, 2022, compared to a net loss of about $6.0 million. Or $0.25 per share, for the three months that ended on September 30, 2021. Reduced research and development costs as well as lower expenses for general and administrative were the main causes of the lower net loss for the three months that ended September 30, 2022 as compared to the three months ending September 30, 2021. Kintara Therapeutics Stock Purchase Procedure Pick a location to purchase Kintara Therapeutics shares. Selecting a stock brokerage is necessary. Open a trading account. Enroll in 0% commission betting with the top brokerage we could find. The greatest location to get KTRA stock is there. Your brokerage account with the money. Add your details and choose your payment method. Analyze the stock of Kintara Therapeutics. The ticker symbol for Kintara Therapeutics is KTRA. Complete the KTRA transaction. Choose whether to buy KTRA stock using a limit order to acquire it at a specific price or at the current market rate. Get up-to-date information on your KTRA investment. Make a watchlist of important updates about your Kintara Therapeutics stock investment. Is This A Good Time To Purchase Shares Of Kintara Therapeutics? The average analyst rating for Kintara Therapeutics among the three Wall Street analysts who follow KTRA is "Hold." On September 29, 2022, Jason McCarthy, a Maxim Group bottom 2% analyst, downgrades KTRA to a hold rating. On May 16, 2022, Jason Kolbert, a Dawson James bottom 7% analyst, downgrades KTRA to a hold rating. On January 20, 2022, Michael King, a bottom 7% analyst at HC Wainwright & Co., keeps KTRA with a buy recommendation but decreases their price objective from $6.00 to $3.00.   Kintara Declares A Reverse One-For-Fifty Stock Split The 1-for-50 reverse KTRA stock split of Kintara's authorized and outstanding common stock will take effect at 5:00 p.m. (EST) on November 11, 2022. Kintara is a biopharmaceutical firm that focuses on the development of innovative solid tumor cancer medicines. The Nasdaq Capital Market will continue to list Kintara's common shares under the ticker "KTRA" and a new CUSIP code, 49720K200. On November 14, 2022, when the market opens, Kintara's common stock will start trading on The Nasdaq Capital Market on a reverse stock divide basis. In order to continue being listed on The Nasdaq Capital Market, Kintara's common stock must trade at a minimum bid price of $1.00 per share, which will be met by the reverse stock split (Nasdaq Listing Rule 5550(a)(2)). Every fifty pre-split shares of ordinary shares that are now outstanding and authorized will be automatically combined into one new share of common stock as a result of the reverse stock split without even any action on the part of the stockholders. Number Of Authorized Shares Of Stocks There will be around 1,616,146 outstanding and issued shares of stockholders as opposed to the 80,807,316 that were granted and current as of November 8, 2022. There will be a drop in the authorized common stock shares from 275,000,000 to 5,500,000. In accordance with the reversal stock split, no mutual funds will be distributed. No stockholders will receive money in lieu of fractional shares as a result of the reverse stock split; rather, any preferred stock of common stock will be rounded up to the closest whole post-split sh

are. The criminal records, vesting units, and stock options of Kintara will also be subject to the reverse stock split, with the conversion and exercise prices thereof being adjusted in accordance with the terms of those securities. The backward stock split will also apply to common shares issuable upon the converting of Kintara's outstanding company stock. What Is The Current Value Of Kintara Stock? KTRA (NASDAQ: ) There are 1,616,146 shares of Kintara Therapeutics outstanding at the moment. The market capitalization of Kintara Therapeutics stock, which is currently trading at $4.43 per share, is $7.05M. On February 22, 2013, Kintara Therapeutics stock went public at a price of $3,400.00. Your return over the past nine years if you had purchased Kintara Therapeutics stock at $3,400.00 would also be -99.87%, for an annualized return of -52.28%. Due Diligence Examines According to our assessment of its fair market value cost of $16.45 depending on discounted cash (DCF) modeling, KTRA ($4.43) is overvalued by 73.5%, but it does not have a substantial margin of safety.  According to our assessment of KTRA's fair value cost of $16.45 based on discounted cash (DCF) modeling, which includes a strong margin of safety, the KTRA stock is currently markedly undervalued at $4.43, a difference of 73.5%. We cannot determine KTRA's intrinsic value using a revised list of Benjamin Graham's method from "The Intelligent Investor" since KTRA is not profitable. In three years, KTRA's Return on Equity is expected to be strong (24.87%); analysts are optimistic about the company's capacity to effectively create return on equity. In comparison to the US Biotechnology sector average (12.5%), KTRA stock forecast is predicted to produce a better Return on Assets (18.11%). The Return on Equity (-193%) of KTRA demonstrates a business that is ineffective at converting shareholders ’ equity into returns. The US Biotechnology sector average (2.32%) is higher than KTRA's Return on Assets (-145.2%). When compared to three years ago (-109.07%), KTRA's capacity to produce Return on Capital has reduced (-220.17%). What Is The Target Price For Kintara? The average KTRA price goal is $3.00, with the top and cheapest KTRA stock forecast both coming in at $3.00, according to one Wall Street analyst who has published a KTRA price target for the next year. By September 29, 2023, the Wall Street analyst projected that Kintara Therapeutics' share price may reach $3.00. From the present KTRA share price of $4.36, the consensus Kintara Therapeutics stock price projection predicts a potential decline of 31.19%. Kintara Therapeutics Stock Price Forecast For 2023 At the time of writing, one share of KTRA stock costs roughly $4.43. Kintara Therapeutics' stock has 3 1 year target prices from Wall Street analysts. Their predictions for the price of KTRA stock forecast range from $150 to $150. They anticipate that within a year, the actual share price will rise to $150. This represents a potential increase from of the stock's market valuation of 3,380.3%. From the most recent price of 4.50, the consensus KTRA stock forecast reflects a +3,182.28% rise. Currently, there is agreement among the two investment analysts that were surveyed to hold Kintara Therapeutics Inc. shares. Until September, when it stayed constant from a hold rating, this rating has remained stable. KTRA Stock Forecast 2024 The revenue for Kintara Therapeutics in 2022 is zero. With the lowest KTRA stock forecast at $31,741,107 and the highest KTRA stock forecast at $31,741,107, 1 Wall Street analysts expect KTRA's revenue will be $31,741,107 on average in 2023. With the lowest KTRA stock forecast coming in at $146,956,156 and the highest KTRA stock forecast coming in at $146,956,156, 1 Wall Street analysts expect KTRA to generate $146,956,156 in revenue in 2024 on average. KTRA Stock Forecast 2025 The revenue for Kintara Therapeutics in 2022 is -$21,661,000. With the cheapest

KTRA stock forecast prognosis being $48,484 and the greatest KTRA earnings projection being $48,484, 1 Wall Street analyst estimated KTRA's earnings to be $48,484 on average for 2023. KTRA stock forecast are expected to be $905,042 on average in 2024, according to one Wall Street analyst, with the lowest and highest estimates both being $905,042. KTRA stock forecast to earn $2,391,896 in 2025, with the lowest and greatest estimates of earnings both coming in at $2,391,896. KTRA is anticipated to create $362,016,704 in revenue in 2025, with $362,016,704 as the lowest and $362,016,704 as the highest revenue projections. Paying dividends is not a source of income for Kintara Therapeutics.  

[stocklivemarket]

A biopharmaceutical firm in the clinical stages called Kintara Therapeutics, Inc. is dedicated to the creation and marketing of innovative cancer treatments. With a focused on orphan cancer indications, the company is creating and marketing anti-cancer treatments for people whose solid tumors display characteristics that make patients resistant to or unlikely to react to existing therapies. The two leading possibilities for the company are VAL-083 and REM-001. Its VAL-083 is a brand-new, approved deoxyribonucleic acid (DNA) targeted agent for the treatment of narcotic solid malignancies such diffuse intrinsic pontine glioma, glioblastoma multiforme. And maybe other solid tumors like ovarian cancer and non-small cell lung cancer (DIPG) REM-001, a delayed photodynamic therapy (PDT) product from the company, is used to treat cutaneous metastatic breast cancer (CMBC). About Kintara Additionally, Kintara offers a unique, late-stage PDT technology that shows promise for treating localized visceral or cutaneous tumors as well as for other possible purposes. People with CMBC who had previously had chemotherapy and/or unsuccessful radiation therapy were enrolled in four Phase 2/3 drug testing to examine the effects of REM-001 therapy. The clinical efficacy of REM-001 in CMBC is currently 80% full remission of CMBC evaluable lesions, and there is a strong safety database of almost 1,100 patients across several indications. To save money, Kintara has suspended the REM-001 CMBC initiative. Who Founded Kintara? The company was established in 2010 and has its headquarters in Canada's Vancouver. We can list its founders as Dennis M. Brown, Jeffrey A. Bacha, Jeffrey Bacha. Since November 8, 2021, Robert E. Hoffman has served as president and chief executive officer, board chairman since June 2018, and director since April 2018. Inc. Aslan Pharmaceuticals He participates inside the Board of Directors as a member. Since October 2018, he has been on the board of directors. Since November 2020, he has also sat on the board of Antibe Therapeutics Inc., where he has served as chairman since May 2022. Editas Medicine, Fulcrum Therapeutics, or Semma Therapeutics are probable rivals and alternatives to Kintara Therapeutics. There are three investors in Kintara Therapeutics, including the Luxembourg National Research Fund and Lincoln Park Capital Fund. What Are Kintara's Academic Collaborations? University of Texas MD Anderson Cancer Center: The goal of Kintara Therapeutics' partnership with MDACC is to investigate how DNA damage response (DDR) pathways affect VAL-083's ability to kill ovarian cancer cells and the potential for combining it with other therapies like PARP inhibitors. University of California San Francisco: By speeding the development of this much needed new medication for GBM, UCSF played a crucial role in expanding patient access and serving as the primary clinical location for our initial clinical trial. UCSF is also testing VAL-083's efficacy versus pediatric elevated glioma and medulloblastoma subtypes, both as a single drug and in combination with other therapies. British Columbia University: The collaboration between Kintara Therapeutics and the University of British Columbia is focused on investigating the DNA repair response (DDR) to VAL-083 therapies in a variety of pediatric brain cancer subgroups (personalized drug treatment) and assessing the potential for topoisomerase inhibitor-combined therapies. Highlights Of The Company And Recent Developments a statement stating that three posters had been approved for presentation of data at the Society for Neuro-Oncology (SNO) Annual Conference in 2022. The 2022 SNO Annual Session will be held in Tampa, Florida, from November 16 to November 20, 2022. (September). Robert E. Hoffman, president and chief executive officer of Kintara, said, "We have focused our VAL-083 program in glioblastoma sufferers and are looking forward to reporting top-line findings in the worldwide registrational GBM AGILE Study before the end of 2023."

"We believe VAL-083 may be an extra tool to help this neglected condition," the statement reads. "GBM patients and clinicians are in need of more medicines to tackle this fatal disease." A Report On The Financial Results For The 2023 Fiscal Year Kintara had about $7.1 million in cash and equivalents as of September 30, 2022. For a net profit to the company of almost $1.9 million during the three months ending September 30, 2022, Kintara concluded the sale of ordinary KTRA stock under a sales contract with Lincoln Park. Kintara reported a net loss of about $4.6 million, or $0.07 per share, for the three months that ended on September 30, 2022, compared to a net loss of about $6.0 million. Or $0.25 per share, for the three months that ended on September 30, 2021. Reduced research and development costs as well as lower expenses for general and administrative were the main causes of the lower net loss for the three months that ended September 30, 2022 as compared to the three months ending September 30, 2021. Kintara Therapeutics Stock Purchase Procedure Pick a location to purchase Kintara Therapeutics shares. Selecting a stock brokerage is necessary. Open a trading account. Enroll in 0% commission betting with the top brokerage we could find. The greatest location to get KTRA stock is there. Your brokerage account with the money. Add your details and choose your payment method. Analyze the stock of Kintara Therapeutics. The ticker symbol for Kintara Therapeutics is KTRA. Complete the KTRA transaction. Choose whether to buy KTRA stock using a limit order to acquire it at a specific price or at the current market rate. Get up-to-date information on your KTRA investment. Make a watchlist of important updates about your Kintara Therapeutics stock investment. Is This A Good Time To Purchase Shares Of Kintara Therapeutics? The average analyst rating for Kintara Therapeutics among the three Wall Street analysts who follow KTRA is "Hold." On September 29, 2022, Jason McCarthy, a Maxim Group bottom 2% analyst, downgrades KTRA to a hold rating. On May 16, 2022, Jason Kolbert, a Dawson James bottom 7% analyst, downgrades KTRA to a hold rating. On January 20, 2022, Michael King, a bottom 7% analyst at HC Wainwright & Co., keeps KTRA with a buy recommendation but decreases their price objective from $6.00 to $3.00.   Kintara Declares A Reverse One-For-Fifty Stock Split The 1-for-50 reverse KTRA stock split of Kintara's authorized and outstanding common stock will take effect at 5:00 p.m. (EST) on November 11, 2022. Kintara is a biopharmaceutical firm that focuses on the development of innovative solid tumor cancer medicines. The Nasdaq Capital Market will continue to list Kintara's common shares under the ticker "KTRA" and a new CUSIP code, 49720K200. On November 14, 2022, when the market opens, Kintara's common stock will start trading on The Nasdaq Capital Market on a reverse stock divide basis. In order to continue being listed on The Nasdaq Capital Market, Kintara's common stock must trade at a minimum bid price of $1.00 per share, which will be met by the reverse stock split (Nasdaq Listing Rule 5550(a)(2)). Every fifty pre-split shares of ordinary shares that are now outstanding and authorized will be automatically combined into one new share of common stock as a result of the reverse stock split without even any action on the part of the stockholders. Number Of Authorized Shares Of Stocks There will be around 1,616,146 outstanding and issued shares of stockholders as opposed to the 80,807,316 that were granted and current as of November 8, 2022. There will be a drop in the authorized common stock shares from 275,000,000 to 5,500,000. In accordance with the reversal stock split, no mutual funds will be distributed. No stockholders will receive money in lieu of fractional shares as a result of the reverse stock split; rather, any preferred stock of common stock will be rounded up to the closest whole post-split sh

are. The criminal records, vesting units, and stock options of Kintara will also be subject to the reverse stock split, with the conversion and exercise prices thereof being adjusted in accordance with the terms of those securities. The backward stock split will also apply to common shares issuable upon the converting of Kintara's outstanding company stock. What Is The Current Value Of Kintara Stock? KTRA (NASDAQ: ) There are 1,616,146 shares of Kintara Therapeutics outstanding at the moment. The market capitalization of Kintara Therapeutics stock, which is currently trading at $4.43 per share, is $7.05M. On February 22, 2013, Kintara Therapeutics stock went public at a price of $3,400.00. Your return over the past nine years if you had purchased Kintara Therapeutics stock at $3,400.00 would also be -99.87%, for an annualized return of -52.28%. Due Diligence Examines According to our assessment of its fair market value cost of $16.45 depending on discounted cash (DCF) modeling, KTRA ($4.43) is overvalued by 73.5%, but it does not have a substantial margin of safety.  According to our assessment of KTRA's fair value cost of $16.45 based on discounted cash (DCF) modeling, which includes a strong margin of safety, the KTRA stock is currently markedly undervalued at $4.43, a difference of 73.5%. We cannot determine KTRA's intrinsic value using a revised list of Benjamin Graham's method from "The Intelligent Investor" since KTRA is not profitable. In three years, KTRA's Return on Equity is expected to be strong (24.87%); analysts are optimistic about the company's capacity to effectively create return on equity. In comparison to the US Biotechnology sector average (12.5%), KTRA stock forecast is predicted to produce a better Return on Assets (18.11%). The Return on Equity (-193%) of KTRA demonstrates a business that is ineffective at converting shareholders ’ equity into returns. The US Biotechnology sector average (2.32%) is higher than KTRA's Return on Assets (-145.2%). When compared to three years ago (-109.07%), KTRA's capacity to produce Return on Capital has reduced (-220.17%). What Is The Target Price For Kintara? The average KTRA price goal is $3.00, with the top and cheapest KTRA stock forecast both coming in at $3.00, according to one Wall Street analyst who has published a KTRA price target for the next year. By September 29, 2023, the Wall Street analyst projected that Kintara Therapeutics' share price may reach $3.00. From the present KTRA share price of $4.36, the consensus Kintara Therapeutics stock price projection predicts a potential decline of 31.19%. Kintara Therapeutics Stock Price Forecast For 2023 At the time of writing, one share of KTRA stock costs roughly $4.43. Kintara Therapeutics' stock has 3 1 year target prices from Wall Street analysts. Their predictions for the price of KTRA stock forecast range from $150 to $150. They anticipate that within a year, the actual share price will rise to $150. This represents a potential increase from of the stock's market valuation of 3,380.3%. From the most recent price of 4.50, the consensus KTRA stock forecast reflects a +3,182.28% rise. Currently, there is agreement among the two investment analysts that were surveyed to hold Kintara Therapeutics Inc. shares. Until September, when it stayed constant from a hold rating, this rating has remained stable. KTRA Stock Forecast 2024 The revenue for Kintara Therapeutics in 2022 is zero. With the lowest KTRA stock forecast at $31,741,107 and the highest KTRA stock forecast at $31,741,107, 1 Wall Street analysts expect KTRA's revenue will be $31,741,107 on average in 2023. With the lowest KTRA stock forecast coming in at $146,956,156 and the highest KTRA stock forecast coming in at $146,956,156, 1 Wall Street analysts expect KTRA to generate $146,956,156 in revenue in 2024 on average. KTRA Stock Forecast 2025 The revenue for Kintara Therapeutics in 2022 is -$21,661,000. With the cheapest

KTRA stock forecast prognosis being $48,484 and the greatest KTRA earnings projection being $48,484, 1 Wall Street analyst estimated KTRA's earnings to be $48,484 on average for 2023. KTRA stock forecast are expected to be $905,042 on average in 2024, according to one Wall Street analyst, with the lowest and highest estimates both being $905,042. KTRA stock forecast to earn $2,391,896 in 2025, with the lowest and greatest estimates of earnings both coming in at $2,391,896. KTRA is anticipated to create $362,016,704 in revenue in 2025, with $362,016,704 as the lowest and $362,016,704 as the highest revenue projections. Paying dividends is not a source of income for Kintara Therapeutics.